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Molecular Characterization of Extended-Spectrum Beta-Lactamase 
Producing E. Coli 
Katia Anis Cheaito 
ABSTRACT 
 
The increasing prevalence of Extended-spectrum Beta-lactamases in many 
countries including Lebanon, a country with a dynamic population represents a 
challenge for the healthcare systems. Given the fact that the incidence of ESBL-
producing bacteria is increasing worldwide and the number of associated nosocomial 
infections is also escalating. This study aimed at determining the increasing prevalence 
of ESBLs in a tertiary care center in Lebanon, identifying the possible associated risk 
factors and medical complications, assessing the clonal relatedness among the isolated 
strains, and identifying the most common resistance genes. Screening for ESBL 
producing E. coli was performed on patients admitted to the ICU for lower GI/ 
urological surgical procedures. Among 75 patients, there were 12 patients who were 
carrying ESBL-producing E. coli on admission and 10 patients who acquired the 
colonization after the surgery. By collecting 3 rectal swabs from each patient, 60 isolates 
were confirmed as ESBL producing and analyzed indiscriminately before the unblinding 
of patients’information. These isolates belonged to 31 PFGE type and each clonal group 
included strains isolated from the same patient at different stages of hospitalization, 
which indicated that the strains are clonally diverse among the different patients. Three 
clonal groups represented an upsetting exception whereby each group included strains 
isolated from 3 different patients and patient to patient transmission was suspected in the 
ICU unit. In addition, ESBL isolates showed alarming broad antibiotic resistance 
profiles and PCR results detected CTX-M-I group as the predominant ESBL type. 
Associated risk factors include age above sixty-one, diabetes, and recurrent urinary tract 
infections which might be predisposing or associated with the colonization of this 
pathogen. These results agree with previously published studies in Lebanon and 
worldwide and highlight the increasing incidence and dissemination of these pathogens 
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in the hospital and community setting and draws attention to the broadening of 
resistance among ESBLs whereby therapy alternatives are becoming scarce.  
Keywords: ESBL, CTX-M, Enterobacteriacae, Multi-drug resistance, E. coli, 
nosocomial infections, Lebanon. 
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CHAPTER ONE 
INTRODUCTION 
 
Since the initial report in Germany in 1983, extended-spectrum β-lactamase (ESBL)-
producing Escherichia coli emerged as a major pathogenic threat worldwide (Knothe et al., 
1983; Paterson & Bonomo, 2005; Livermore et al., 2007; Pitout& Laupland, 2008; Hawser 
et al., 2009; Qian-Hong et al, 2011) 
The increasing prevalence of ESBL producing pathogens and their alarming 
evolution can be attributed to the frequent prescription of β-lactam agents such as penicillins, 
cephalosporins, monobactams and carbapenems. Indeed, ESBLs were identified shortly after 
the introduction of oxyimino-β-lactam antibiotics (Medeiros, 1997; Pitout et al, 2005; 
Bourjilat et al, 2011). 
Initially, the classic ESBLs occurred due to mutations in the genes encoding the 
common plasmid-mediated TEM-1 and SHV-1 enzymes (Jacoby & Munoz-Price, 2005). 
More recently, a novel group of ESBLs, the CTX-M family, have emerged and rapidly 
disseminated worldwide (Canton & Coque, 2006). The bla CTX-M genes are found on 
transferable plasmids from the chromosomes of Kluyvera spp., and their products are now 
the most widespread ESBLs (Livermore et al, 2007). This CTX-M emergence led to further 
dissemination of ESBLs in both community and hospital settings, predominantly in 
developing countries (Woerther et al, 2011). 
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According to Pitout et al (2005), the world is now experiencing a situation for ESBL-
producing bacteria that parallels the epidemiology of methicillin-resistant Staphylococcus 
aureus. In both situations, resistance was initially reported in nosocomial pathogens, and 
later on community acquired cases appeared (Chambers, 2001). Therefore, the early 
detection of ESBL-producing organisms and their resistance patterns is essential for the 
prevention of the progress and dissemination of this resistance (Pitout et al, 2005). 
Moreover, Multi-drug resistant (MDR) organisms like ESBLs represent a threat for 
the actual health care systems since they may increase morbidity, mortality, hospital stay and 
treatment expenses (Bradford, 2001; Carattoli et al, 2008). Thus, it is of utmost importance 
to follow up with the resistance patterns of bacteria to prevent the development and 
dissemination of this resistance (Qian-Hong et al, 2011). 
In Lebanon, as in other countries, the prevalence of ESBL-producing bacteria is 
increasing (Kanafani et al, 2005; Daoud & Afif, 2011). More specifically, the CTX-M type 
of ESBLs is predominant and rapidly disseminating (Moubareck et al, 2005). In addition, 
recent reports highlighted the initiation of resistance to the treatment of choice for serious 
ESBL associated infections i.e. carbapenems among ESBL producing isolates (Baroud et al, 
2012).  
Stool samples were collected from patients admitted to the intensive care unit (ICU) 
for elective lower gastro-intestinal / urogenital surgeries at the University Medical Center 
Rizk Hospital (UMCRH), screening for ESBL production was performed by rectal swabs or 
stool cultures pre- and post- surgery, and the positive samples were included in the study. 
Patients were requested to fill a questionnaire including the risk factors for ESBL possible 
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carriage. Pulsed-Field Gel Electrophoresis (PFGE) analysis was performed on all ESBL 
producing E.coli isolates to generate their DNA banding patterns and determine their clonal 
relationship, and polymerase chain reaction (PCR) was performed to assess the prevalence of 
CTX-M production among the ESBL isolates. The results obtained corroborated the fact that 
CTX-M producing ESBLs are the most predominant in Lebanon and revealed high rates of 
antibiotic resistance against third-generation cephalosporins, aminoglycosides, and 
fluoroquinolones. PFGE fingerprints indicated clonal diversity among the tested strains 
except for groups A17 and A18 where patient to patient transmission of the same strain is 
suspected.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
 
2.1 Overview of  Escherichia coli 
The genus Escherichia is named after Theodor Escherich, who isolated the type 
species of the genus in 1885 (Nataro & Kaper, 1998). E. coli is a major facultative 
anaerobic non-pathogenic inhabitant of the large intestine. Some virulent strains, 
however, represent one of the most common causes of many bacterial infections, 
including urinary tract infection (UTI), intestinal diseases and neonatal meningitis 
(Nataro & Kaper, 1998). Furthermore, among Gram-negative pathogens, E. coli is 
considered one of the most widespread causes of both community-acquired and 
nosocomial bloodstream infections (Gaynes et al, 2005).  
Drug-resistant strains of E. coli are becoming progressively more frequent due to 
the rampant use of antibiotics. Such infections are more likely to result in therapy failure 
and entail more extended, complicated treatment (Lepelletier et al, 1999). 
2.2 History of Antimicrobial Resistance 
The treatment of infectious diseases using drugs dates back to the 17th century; 
nonetheless the modern era of antimicrobial chemotherapy started in the mid 1930s with 
the introduction of the sulfonamides. These synthetic chemicals represent the first 
medicine capable of treating potentially-lethal bacterial infections, including 
streptococcal infections pneumonia, and meningitis (Lesch, 2007). Nonetheless, the 
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accidental discovery of penicillin by Fleming in the early 1940s and its clinical use mark 
the official start point of the antibiotic era (Harrison & Svec, 1998). Following on the 
heels of penicillin production by Penicillium chrysogenum came the discoveries of 
cephalosporin formation by Cephalosporium acremonium, cephamycin, clavam and 
carbapenem production by actinomycetes, and monocyclic β-lactam production by 
actinomycetes and unicellular bacteria (Demain & Elander, 1999).  
Since that time, seventy years of sturdy development has followed, and at present 
the β-lactam antibiotics are the most thriving example of natural product chemotherapy 
(Moreillon et al, 1995; Demain & Elander, 1999). These discoveries gave the illusion that 
total therapeutic control of most bacterial infections is established by these drugs.  
However, the unrestrained use of these agents led to the recurrence of bacterial threat to 
human health. These microorganisms were able to develop resistance to antibiotics 
through mutations and genetic exchange of resistance determinants (Moreillon, 1995; 
Harrison & Svec, 1998).  
. 
2.3 β-lactam antibiotics:  
The β-lactam antibiotics are a broad class of antibiotics that comprise the 
penicillins, cephalosporins, carbapenems, and monobactams. Their name is derived from 
the existence of a β-lactam ring in their molecular structure (Ensor & Hawkey, 2007; 
Shahid et al, 2011). 
Penicillin represents the first member of this class which was derived from molds of 
the genus Penicillium. Later on, natural β-lactams were derived from both molds and 
bacteria of the genus Streptomyces. Nowadays, β-lactams can be synthesized but they are 
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mostly derived from semi synthetic processes involving the chemical modification of the 
products of fermentation (Demain & Elander, 1999). 
 
2.3.1 Classification of β-lactam antibiotics: 
The β-lactams are classified according to their chemical structure. The β-lactam 
ring can be singular like in the case of monobactams, fused to a five-member penem ring 
in penicillins and carbapenems, or fused to a six member cephem ring in cephalosporins. 
Among these major groups, additional differences in the side chain(s) attached to the 
single or double ring can affect their pharmacologic properties significantly (Ray & 
Ryan, 2010). 
2.3.2 Mode of Action of β-lactam antibiotics: 
β-lactam drugs are selective inhibitors of  bacterial cell wall synthesis. Their action 
starts with binding of the drug to cell receptors or penicillin-binding proteins (Deck D.H., 
2012). After binding to one or more receptors, the transpeptidation reaction is inhibited, 
and peptidoglycan synthesis is blocked, this will be followed by removal or inactivation 
of an inhibitor of autolytic enzymes in the cell wall, which will result in cell lysis (Deck 
D.H., 2012). 
2.3.3 Mechanisms of bacterial resistance to β-lactams: 
Bacterial antibiotic resistance is acquired through mutations in genes targeted by the 
antibiotic and the exchange of resistance features found on plasmids, transposons or 
bacteriophages. This transfer takes place through transduction by bacteriophages, 
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transformation by incorporating chromosomal DNA from dying organisms, or through 
conjugation via transposons and plasmids (Levy & Marshall, 2004). 
 
In the case of β-lactam drugs, bacterial resistance is manifested through the 
organism's production of penicillin-destroying enzymes or β-lactamases (Shahid et al, 
2009). β-lactamases can be plasmid mediated or chromosomally mediated (Alekshun & 
Levy, 2007; Shahid et al.,2009). These β-lactamases open the β-lactam ring of penicillins 
and cephalosporins and impede their antimicrobial activity (Shahid et al, 2009). 
The production of β-lactamases in Gram-negative bacteria represents a threatening 
global problem that makes bacteria immune against the toxic effect of β-lactam 
antibiotics (Shahid et al, 2011). Therefore, as an attempt to battle the β-lactamase 
mediated resistance, third generation cephalosporins were launched into clinical practice 
in the early 1980s.  Thus, oxyimino-cephalosporins such as cefotaxime and ceftazidime, 
which are intrinsically less vulnerable to β-lactamases, were introduced to treat infections 
caused by β-lactams resistant Gram-negative bacilli (Shahid et al, 2011). Consequently, 
and as a result of the increased use of these newly developed cephalosporins, resistant 
strains appeared which produced extended-spectrum beta-lactamases (ESBLs) (Naas & 
Nordmann, 1999; Bradford, 2001). Actually, ESBLs that mediate resistance to oxyimino-
cephalosporins have now been observed worldwide in all species of Enterobacteriaceae 
(Bradford, 2001). 
2.4 ESBLs 
Since the 1980s, Enterobacteriacae producing ESBLs were established as a major 
cause of nosocomial infections (Pitout, 2005). In 1983, the first plasmid-encoded β-
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lactamase, capable of hydrolyzing extended-spectrum β-lactam antibiotics, was described 
in Germany (Bush & Sykes, 1983). These enzymes are termed ESBLs since they confer 
bacterial resistance to penicillins, first-generation, second-generation, third-generation 
cephalosporins and aztreonam, but not to cephamycin, carbapenems or β-lactamase 
inhibitors (Tham et al., 2012; Patterson & Bonomo, 2005; Drawz & Bonomo, 2010). 
ESBLs have serine at their active site which enables the destruction of the amide bond of 
these antibiotics leading to their hydrolysis (Chaudhary & Aggarwal, 2004).  
Moreover, although ESBLs have been depicted in a wide variety of 
Enterobacteriaceae and Pseudomonadaceae; they are mostly identified in K.  
pneumoniae and E. coli (Shahid et al, 2011).  
Organisms producing ESBLs are clinically important and represent a major cause 
for failure of treatment with cephalosporins (Bush, 2001; Bradford, 2001). ESBLs are 
mostly encoded by genes found on large plasmids which include as well genes encoding 
resistance for a variety of antimicrobial agents including aminoglycosides, 
sulphonamides, trimethoprim, chloramphenicol and tetracyclines (Paterson, 2000). 
Consequently, ESBLs are characterized by a broad antibiotic resistance extending to 
multiple classes (Bradford, 2001). This resistance is even extending to carbapenems 
which represent the treatment of choice for ESBL associated serious infections (Rahal, 
2008; Doumith et al, 2009). 
A number of risk factors, predisposing for ESBL infections, are identified 
including: duration of hospital stay, severity of sickness, time in the ICU, mechanical 
ventilation and intubations, arterial or urinary catheterization, and previous exposure to 
antibiotics (Bradford, 2001). Furthermore, most ESBL-producing organisms have been 
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reported from hospitalized patients admitted to ICUs, but infections can occur in almost 
any area of the hospital, as well as in long-term care facilities, and nursing homes 
(Bradford et al, 1995; Livermore, 2003; Kassis-Chikhani et al, 2004). In addition, these 
organisms are isolated with rising incidence from patients with community-onset disease 
(Arpin et al, 2003; Pitout et al, 2004).  
2.4.1 ESBLs and their classification 
According to the Ambler classification, β-lactamases are classified into four 
classes, A to D, on the basis of their amino acid sequences and non-phenotypic 
characteristics, with classes A and C being the most frequent (Ambler, 1980). In this 
classification system, ESBLs of classes A, C and D are serine β-lactamases, and the class 
B enzymes are metallo-β-lactamases (Jacoby, 1994).  
Historically, mutations in the genes encoding the common plasmid-mediated 
TEM-1 and SHV-1 enzymes were the initial cause for the occurrence of ESBLs (Jacoby 
& Munoz-Price, 2005). TEM-1 designation is related to Temoniera, the patient from 
whom it was initially isolated in Greece and SHV-1 is named after the sulfhydryl 
“variable” active site (Patterson & Bonomo, 2005). These ESBLs represent the “classic” 
enzymes with hydrolytic activities against newer penicillins, cephalosporins, and 
aztreonam (Jorgensen, 2010). Currently, 175 different TEM enzymes and 127 SHV 
different enzymes are described (www.lahey.org/studies/). Nevertheless, a new group of 
ESBLs, the CTX-M family, have emerged and spread rapidly worldwide (Canton & 
Coque, 2006). 
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2.5 CTX-M class of ESBLs and their classification 
Recently, the CTX-M-type ESBLs were established as a major cause of antibiotic 
resistance (Gniadkowski, 2001). These enzymes are prominent among 
Enterobacteriaceae from Europe, Africa, Asia, South America and North America 
(Bonnet, 2004).  
CTX-M β-lactamases result from point mutations of TEM-type and SHV type β-
lactamases and are distinguished from most TEM and SHV ESBLs by their preferred 
ability to hydrolyze cefotaxime over ceftazidime (Tzouvelekis, 2000). They are termed 
CTX-M since they are active on Cefotaxime and they were first isolated at Munich 
(Shahid et al, 2011). CTX-Ms were produced by plasmid exchange from chromosomal 
ESBL genes from Kluyvera spp., which characteristically are nonpathogenic organisms 
(Bonnet, 2004; Babic et al, 2006; Livermore et al, 2007).  
Moreover, the significant increase in the number of ESBLs reported worldwide is 
attributed to the fast and broad dissemination of CTX-M-type ESBLs (Livermore & 
Hawkey, 2005; Livermore & Woodford, 2006).  The recurrent proliferation of isolates 
with CTX-M enzymes is of significant public health concern, thus, monitoring the 
prevalence and development of CTX-M enzymes is of utmost importance (Ensor et al, 
2007). 
2.5.1 Phylogenetic properties of CTX-M-producing E. coli 
CTX-M-producing E. coli are classified into five phylogenetic groups, most or all 
of which developed from the chromosomal β-lactamases of Kluyvera spp. (Bonnet, 2004; 
Olson, 2005; Poire, 2002). At present, The number of CTX-M β-lactamases, identified 
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exceeds more than 90 different variants which can be classified, based on their amino 
acid structure, into five distinct phylogenetic groups namely groups 1, 2, 9, 8 and 25/26 
(Bonnet, 2004). The CTX-M-1 group including: CTX-M-1, -3, -10, -12,-15, -28, -30 and 
FEC-1, the CTX-M-2 group including: CTX-M-2,-4, -5, -6, -7, -20 and Toho-1, the CTX-
M-8 group including: CTX-M-8, the CTX-M-9 group including: CTX-M-9, -13, -14 (also 
named CTX-M-18), -16, -17, -19, -21, -24, -27 and Toho-2, and the CTX-M-25 group 
with CTX-M-25 and CTX-M-26 (Pitout et al, 2005). 
2.5.2 Epidemiology of CTX-M-producing E.coli 
The number of CTX-M-type ESBLs is rapidly escalating and they were identified 
in every inhabited continent (Patterson & Bonomo, 2005). For a period of time, CTX-M 
ESBLs were mainly detected in three geographic regions: South America, the Far East, 
and Eastern Europe while they appeared to be sporadic in Western Europe and North 
America, however, more recently, the arrival of CTX-M-type ESBLs in these regions 
have been reported extensively (Dechamps et al, 2000).  Furthermore, CTX-M-type 
ESBLs were largely reported in China and India, and hence CTX-M-type ESBLs can be 
considered as the most prevailing ESBL type (Pitout et al, 2005).  
In addition, some of the CTX-M enzymes were identified in particular countries, 
like CTX-M-1 in Italy, CTX-M-9 and CTX-M-14 in Spain, and CTX-M-2 in the majority 
of South American countries and Japan, while CTX-M-15 was detected worldwide 
(Bonnet, 2004; Ben-Ami et al, 2006; Canton & Coque, 2006). However, CTX-M-14 was 
identified as being the most prevalent in a broad geographic area which includes North 
America, Europe, and south and east Asia, while a number of CTX-M-32-producing 
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strains were recently detected in both humans and farm animals in Spain, Italy, Greece 
and Portugal (Eckert et al, 2006). This suggested the presence of a community reservoir 
of CTX-M enzymes disseminating in the Mediterranean area (Cartelle et al, 2004; Oteo et 
al, 2006).  
2.5.3 CTX-M-producing E.coli in Lebanon 
 
In Lebanon, an increase in the prevalence of ESBL-producing bacteria was 
observed from 2.3% in 2000 to reach 8% in 2005 and 16.8% in 2009 (Kanafani et al, 
2005; Daoud & Afif, 2011). The escalating numbers of ESBL-producing bacteria were 
not only noted for E. coli, but also for K. pneumoniae, Salmonella spp. and Shigella spp 
(Araj et al, 2012). In addition, in a recent study, resistance to carbapenems; which 
represent the preferred treatment for severe infections with ESBL-producing organisms, 
was detected in ESBL E. coli and K. pneumoniae at a tertiary care center in Lebanon 
(Baroud et al, 2013).  
The predominance and fast emergence of the CTX-Ms has been reported in 
Lebanon (Moubareck et al, 2005). Sequence analysis indicated that the bla-CTX-M gene 
is bla-CTX-M-15 was carried on a 90 kb plasmid and flanked by an insertion element 
(ISEcp1) (Matar et al, 2007; Baroud et al, 2013). The occurrence of bla-CTX-M-15 in 
other Enterobacteriaceae in Lebanon (Moubareck et al, 2005) indicates that the spread of 
extended-spectrum beta-lactam resistance results typically from horizontal transfer of this 
plasmid-borne gene (Sabra et al, 2009). 
In addition, probably due to study design differences, previous studies in Lebanon 
do not have concurred results. In one study, 61 ESBL producing E. coli samples were 
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isolated in a major Hospital in South Lebanon, but none of the isolates carried the CTX-
M gene (Matar et al, 2005). In a more recent study, most of the ESBL isolates collected at 
the American University of Beirut (AUB-MC) (96.1%) carried a blaCTX-M gene (Kanj et 
al, 2008).  
2.6 Pulsed-field gel electrophoresis (PFGE) 
 
PFGE is a widely implemented DNA “fingerprinting” method for determining 
isolate interrelatedness (Goering, 2010). It includes embedding the microorganisms in 
agarose, lysing the cells in situ, and digesting the chromosomal DNA with restriction 
endonucleases that cleave infrequently yielding large DNA molecules (Tenover et al, 
1995). Xba I is an example of enzymes with hexanucleotide recognition sequence 
(50T^CTAGA30) that is used to infrequently cleave the G + C rich genomes of Gram-
negatives like in the case of E. coli. 
 The importance of PFGE relies in its ability to resolve DNA molecules over a 
wide range of sizes from kb to Mb (Goering, 2010). This technique represents a variation 
of conventional agarose gel electrophoresis in which the direction of the electric field 
across the gel is changed periodically. This modification, developed by Schwartz and 
Cantor (1984), enables large fragments to be separated according to size (Akpaka & 
Jayaratne, 2012). Genetic events, including insertions, deletions, rearrangements, and 
substitutions, can influence the PFGE pattern obtained. Indeed, these changes can affect 
the sites at which the restriction enzyme cleaves and result in a size-dependent change in 
the electrophoretic migration rate (Goering, 2010).  
Different PFGE instrumentation approaches are available, but the most widely 
used is contour-clamped homogenous electric field electrophoresis (CHEF). In this 
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apparatus, hexagonally arranged electrodes and suitable voltages are employed to 
produce homogeneous electric fields and an angle of re-orientation of 120, thus, allowing 
the separation of fragments up to 2-3 Mb in size (Chu et al, 1986; Akpaka & Jayaratne, 
2012). 
 
Furthermore, the interpretation of DNA fragment patterns by PFGE and 
transforming them into epidemiologically useful information is based on guidelines 
proposed by Tenover et al. (1995), and depends on computer-assisted analysis such as 
GelCompar and BioNumerics to facilitate the comparison among a large number of 
isolates (Goering, 2010). 
The main difficulties encountered when using PFGE are the technical 
requirements of the procedure, price of the reagents and equipments and the time needed 
to perform the test (Olive & Bean, 1999). Nevertheless, since its development, PFGE has 
been recommended as a 'gold standard' for typing of outbreak strains (Cookson et al., 
1996).  It is one of the most reproducible and highly discriminatory typing methods that 
can help trace the transmittance of multi-drug resistant bacteria such as ESBL enzyme 
producing pathogens and allows the determination of the sources and the clonal 
relatedness of bacterial isolates; hence, it can be implemented as a means for infection 
control in a hospital (Akpaka & Jayaratne, 2012). 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1 Clinical Isolates 
 
During a period of 6 months, a blinded study was conducted from February 2013 to 
August 2013, seventy five patients were admitted to the ICU at UMCRH for urological or 
abdominal surgeries. Upon their admission and patient approval, screening for ESBL was 
done by taking three consecutive stool/rectal swab cultures. The first fecal sample was 
collected prior to surgery and the other two in the following week. The following variables 
were recorded: age, sex, occupation, type of surgery, dates of admission and discharge from 
the ICU, previous surgical procedures or previous hospitalization, underlying medical 
conditions, and previous exposure to antibiotics. Variables concerning antibiotic treatments 
before and after surgery were also noted, and the patients were followed for two months after 
the surgical procedure to monitor the occurrence of any complication or post-surgical 
infection. All samples received were analyzed in the lab indiscriminately until the unblinding 
was permitted and patients’ numbers were made available for the analysis. The samples were 
streaked on Tryptone Soy Agar (TSA) and stored in Cryobanks at -80°C. Patients were 
designated as p1 to p75, and samples collected previously during 2012 with no patient 
information were designated an x1 to x12. 
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3.2 Antibiotic Susceptibility Testing 
 
Antimicrobial susceptibility testing was performed to determine the resistance 
patterns of the isolates by the Kirby-Bauer disk diffusion method according to the 
recommendations of the Clinical and Laboratory Standards Institute (CLSI, 2011). All ESBL 
isolates were streaked on Mueller-Hinton agar (Oxoid) and incubated at 37˚C for 24h with 
the following antibiotics: cefotaxime, ceftazidme, aztreonam, gentamicin, ciprofloxacin, 
amoxicillin/clavulanic acid, imipenem and meropenem (Oxoid, England). Table 1 
summarizes the zone of inhibition (ZOI) for each antibiotic along with the concentration (μg) 
as recommended. 
Table 1 Zone of inhibition (mm) for the tested antibiotics according to CLSI recommendations (2011). 
Antibiotic (μg) ZOI (mm) Antibiotic (μg) ZOI (mm) 
 
 
S I R S I R 
Gentamicin (10) ≥ 15  13–14 ≤ 12 Cefotaxime (30) ≥ 26 23-25   ≤ 22 
Imipenem (10)  ≥ 23 20–22 ≤ 19 Ceftazidime (30) ≥ 21  18–20    ≤ 17 
Cefepime (30) ≥ 18 15–17 ≤ 14 Ciprofloxacin (5) ≥ 21  16–20 ≤ 15 
Aztreonam (30) ≥ 21 18–20   ≤ 17 Amoxicillin-
clavulanic acid 
(20/10) 
≥ 18  14–17 ≤ 13 
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3.2 ESBL Detection and Confirmation 
 
The standard disk diffusion method was used for screening ESBL production in all 
strains according to the recommendations of the CLSI (2011). All isolates were streaked on 
MH agar and incubated at 37˚C for 24h. The table below indicates the ZOI of specific 
antibiotics including Ceftazidime, Aztreonam, and Cefotaxime that may indicate ESBL 
production. 
 
Table 2 Zone of inhibition (mm) when screening for ESBL production according to CLSI recommendations 
(2011) 
Antibiotic (μg) ZOI (mm) 
Ceftazidime (30)  ≤ 22 mm 
Aztreonam  (30) ≤ 27 mm 
Cefotaxime (30)  ≤ 27 mm 
 
For confirmation of ESBL production, potassium clavulanate (Fluka 33454), an 
inhibitor of ESBL production, is added to ceftazidime and cefotaxime disks using a stock 
solution of 1000 μg/mL; 10 μL of clavulanic acid were added to ceftazidime (30 μg) and 
cefotaxime (30 μg) disks allowing about 30 minutes for the clavulanic acid to absorb and the 
disks to be dry enough for application. The standard CLSI disk tests were performed on MH 
agar and incubated for 18 h at 37°C. ESBL production was confirmed if there was an 
increase of at least 5 mm in the zone diameter from the clavulanate combination test 
compared to that from the test with cephalosporin substrate. E. coli ATCC25922 and K. 
pneumonia ATCC700603 were used as negative and positive control strains respectively, 
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which were tested routinely. Table 2 summarizes the expected increase in zone diameter for 
the antimicrobial agents tested vs. its zone when clavulanic acid is added with the control 
strains according to the CLSI standards (2011). 
Table 3 Confirmation of ESBL production; the increase in zone diameter (mm) for the control strains 
according to CLSI standards (2011). 
 Increase in Zone diameter (mm)
 
 Cefotaxime-
clavulanic acid
  
Ceftazidime-
clavulanic acid
  
E. coli ATCC® 25922
 
≤ 2-mm
 
≤ 2-mm
 
K. pneumonia ATCC700603
 
≥ 3-mm
 
≥ 5-mm
 
 
3.3 Pulsed-Field Gel-Electrophoresis 
The clonal relationship between the different ESBL isolates was studied by PFGE. 
PFGE of chromosomal DNA digested with the restriction enzyme XbaI was carried out 
according to the “Standardized Laboratory Protocol for Molecular Subtyping of Escherichia 
coli O157:H7 by Pulsed Field Gel Electrophoresis (PFGE)” protocol. Briefly, few colonies 
from fresh cultures are resuspended in Cell Suspension Buffer (CSB).  An aliquot of 400 μl 
adjusted cell suspension is mixed with 20 μl of Proteinase K (20 mg/ml stock) and 400 μl 
melted 1% SeaKem Gold agarose. Immediately, a part of the mixture is disposed into the 
appropriate well(s) of reusable plug mold. Plugs were allowed to solidify at room 
temperature for 10-15min. The plugs are then incubated in 5ml of Proteinase K/Cell Lysis 
Buffer in a 54-55ºC shaker water bath for 2h with constant and vigorous agitation (150-175 
rpm). Then, plugs are washed with preheated sterile Ultrapure water two times and with TE 
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buffer another four times. A 2 mm wide slice was cut and the remaining of the plug was 
stored at 4˚C for later usage. The slice is incubated in 200 μl restriction buffer at 37 ºC for 5-
10 min. Then the buffer is discarded and 200 μl restriction enzyme mixture; XbaI restriction 
enzyme and Tango buffer (Fermentas ER0682) is added to each plug slice and the samples 
are incubated at 37°C for 2 h. To stop the reaction, the restricted plug slices are washed with 
0.5X Tris-borate-EDTA buffer (TBE). Three plug slices of Bio-Rad Lambda ladder are 
regenerated in 0.5X TBE for 10 min at 45 ºC, and run along with the samples. The bands 
were resolved with a 1% agarose gel in 0.5X TBE and run in the contour-clamped 
homogeneous electric field (CHEF-DRIII) System electrophoresis apparatus (Bio-Rad, 
Hercules, CA) using 2 L 0.5X TBE with an initial time 2.2 and a final time 54.2 at 14˚C for 
20 h. After staining with ethidium bromide, the bands were visualized under UV 
(SYNGENE-G: box). Cluster analysis was performed with GelCompar II® software 
(Applied Maths, Sint-Martens-Latem, Belgium) using dice coefficient and visualized as a 
dendogram by the unweighted pair group method (UPGMA), using average linkages with 
1% tolerance and 1% optimization settings. A similarity cutoff of 80% was used to define a 
cluster. 
 
3.4 CTX-M subtyping 
3.4.1 Positive control strains 
 
An isolate producing CTX-M 15 was kindly provided by Dr. Ghassan Matar from the 
American University of Beirut Medical Center (AUB-MC) and was used as a positive PCR 
control for identifying CTX-M group I. 
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3.4.2 DNA template preparation 
 
Few colonies of an overnight culture (18 to 24 h) on a TSA agar plate were 
inoculated in 100 μl of distilled water. Then the cells were lysed by heating at 95°C for 10 
min, and centrifugation at 15,000 rpm for 5 min was applied to remove cellular debris. The 
supernatant was utilized as a source of template used for PCR amplification (Doyle et al, 
2012). 
3.4.3 Molecular detection of CTX-M genes 
 
The protocol adapted from Xu et al (2005) was standardized using a positive control 
for CTX-M group I All ESBL isolates were subject to a monoplex PCR to detect the 
prevalence of CTX-M group 1. 
The optimal cycling parameters were as follows: 95°C for 1min; 30 cycles of 95°C 
for 1s, 55°C for 1min, and 72°C for 1min; with a final extension at 72°C for 10 min. The 
reaction mixtures included 25 μl AmpliTaq Gold® PCR Master Mix (Applied Biosystems); 
which contained 250 U (0.05 U/μL) AmpliTaq Gold DNA Polymerase, GeneAmp PCR Gold 
Buffer (30 mM Tris/HCl, 100 mM KCl), 400 μM of each dNTPand 5 mM MgCl2. 1 μg of 
chromosomal template was added to the master mix with 2 μl of each primer and RNase-free 
water to a final volume of 50 μl. The PCR product was resolved on a 1.5 % (w/v) agarose gel 
in 1X Tris-Acetic Acid-EDTA (TAE) buffer at 100 V for 45 min. The amplified products 
were visualized with UV light after staining with ethidium bromide. Table below includes 
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the PCR primer set used to amplify CTX-M group I and size of the expected product as 
adapted from Pitout et al (2004). 
 
Table 4 Primers used for amplification of CTX-M genes as described by Pitout et al (2004). 
Target Orientation Oligonucleotide sequence (5’ 3’) 
 
Product size  
CTX-M group I Forward GAC GAT GTC ACT GGC TGA GC 499 
 Reverse AGC CG C CGA CGC TAA TAC A  
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CHAPTER FOUR 
RESULTS 
4.1 Clinical isolates 
4.1.1 Clinical information 
 Screening for ESBL producing E. coli was performed in the period 
between February 2013 to August 2013 for 75 patients admitted to the ICU for surgical 
procedures. These patients were 60% male and 40% female. The main surgeries 
performed were Cystoscopy (29%) and Cholecystectomy (13%), and no complications 
during these surgeries were reported. The age of 58% of ESBL carriers was above 61 
(Figure 1). As for risk factors, Figure 2 shows the association between risk factors within 
the ESBL and non-ESBL carriers. 
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Figure 1 The frequency of patients (percent) among different age groups; less than 18 years, between 19  
and 30 years, between 31  and 40 years, between 41  and 50 years, between 51  and 60 years, between 61  
and 70 years, and more than 71 years. 
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Figure 2 The frequency of possible risk factors among patients 
4.1.2 ESBL prevalence 
Results obtained indicated that among the seventy five patients included in the 
study, twenty two patients were carrying ESBL producing E.coli. Figure 3 shows the 
percentage of ESBL carriers among the 75 patients admitted to the ICU for intestinal 
surgeries and included in the study. Table 5 shows the time of ESBL colonization relative 
to the surgery performed.  Three rectal swabs were taken from each patient pre- and post-
surgery to determine if ESBL incidence was due to prior colonization, was acquired 
during hospitalization or was eliminated after surgery and treatment with antibiotics.   
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Figure 3 Prevalence of ESBL colonization among all patients included in the study. 
 
Table 5 Distribution of ESBL carrying patients according to the time of pathogen isolation; three 
rectal swabs were screened for ESBLs, one before surgery and two after the surgery. 
 ESBL distribution  Number of patients 
ESBL detected prior to surgery 2 
ESBL detected post-surgery 10 
ESBL detected prior and post-surgery 10 
 
 
4.2 Antibiotic susceptibility testing 
  
4.2.1 Antibiotic resistance patterns 
According to the guidelines of CLSI (2011), 60 (100%) of the isolates exhibited 
resistance to cefotaxime (3rd generation cephalosporin) and susceptibility to Imipenem 
(carbapenem). It is noteworthy that 28 isolates (45%) were detected as resistant to cefepime 
(fourth generation cephalosporin), 47 isolates (78%) were resistant to ciprofloxacin 
(fluoroquinolone), and 22 isolates (38.3%) displayed resistance to gentamicin 
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(aminoglycoside). Among all isolates, no carbapenem resistance was detected. Table 6 below 
summarizes the percentage of resistance among the ESBL isolates for each antibiotic tested. 
 
Table 6 Antibiotic resistance patterns among the ESBL isolates 
  Antibiotic (μg) Number of resistant isolates (%) 
Cefotaxime (30 μg) 60 (100) 
Aztreonam (30 μg) 53 (88.3) 
Ciprofloxacin (5 μg) 47 (78.3) 
Ceftazidime (30 μg) 51 (85) 
Cefepime (30 μg) 27(45) 
Gentamicin (10 μg) 23 (38.3) 
Amoxicillin-clavulanic acid (20/10 μg) 16 (26.6) 
Imipenem (10 μg)  0 (0) 
 
 
 
4.2.2 Resistance profiles 
 
Nineteen different resistance profiles were generated by the isolates tested. 
Approximately 28% of the isolates showed simultaneous resistance to third-generation 
cephalosporins, aminoglycosides, and fluoroquinolones (GM CIP CTX ATM CAZ). 
Table 7 summarizes the 17 resistance profiles and their percentages. 
 
Table 7 The different resistance profiles and their respective percentage among the ESBL isolates 
Resistance Profile Number of Isolates (%) 
CTX 2 (3.3) 
GM-CTX 1 (1.6) 
 26 
 
CTX-ATM-CAZ 3 (5) 
GM-CTX-AMC 1 (1.6) 
GM-CIP-CTX 2 (3.3) 
CIP-CTX-ATM 2 (3.3) 
CTX-ATM-CAZ-AMC 3 (5) 
GM-CTX-ATM-CAZ 2 (3.3) 
CIP-CTX-ATM-CAZ 1 (1.6) 
FEP-CIP-CTX-ATM 2 (3.3) 
FEP-CIP-CTX-ATM-CAZ 17 (28.3) 
CIP-CTX-ATM-CAZ-AMC 3 (5) 
GM-CIP-CTX-ATM-CAZ 9 (15) 
GM-FEP-CIP-CTX-ATM-CAZ 4 (6.6) 
GM-CIP-CTX-ATM-CAZ-AMC 3 (5) 
FEP-CIP-CTX-ATM-CAZ-AMC 2 (3.3) 
GM-FEP-CIP-CTX-ATM-CAZ-AMC 3 (5) 
 
4.3 ESBL production confirmation 
 
The ESBL production was confirmed when an increase of at least 5 mm in the 
zone diameter was observed for CAZ/CLA compared with that for CAZ alone, or for 
CTX/CLA compared with that for CTX alone. In fact, the ESBL phenotype was 
confirmed with both cefotaxime and ceftazidime but more evidently with cefotaxime 
suggesting that the samples belong to CTX-M group of ESBLs (figure 4). 
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Figure 4 Representative of confirmed ESBL production using cefotaxime and ceftazime disks compared with 
cefotaxime/clavulanic and ceftazidime/clavulanic respectively on MH agar media plate; more than 5 mm 
increase in the zone diameter  observed for CAZ/CLA compared with that for CAZ and for CTX/CLA 
compared with that for CTX. 
 
4.4 Pulsed-field gel-electrophoresis (PFGE) 
 
 All ESBL confirmed isolates were subjected to PFGE typing. Fifty-six out of 
the 60 isolates were typeable by XbaI macrorestriction and produced different pulsotypes 
according to the criteria defined by Tenover et al. (1995).  The remaining four isolates were 
not typeable by PFGE. Figure 5 is a representative of gel electrophoresis revealing the 
patterns generated by PFGE and Figure 6 includes a dendogram of PFGE clusters of all 
isolates. Thirty one clonal groups designated as A1-A31 were defined by employing 80% 
similarity as cutoff with isolates being distributed as: group of five (A17), 2 groups of four 
isolates (A16 + A18), four groups of three isolates (A1 + A3 + A13 + A22), five groups 
containing two isolates(A5 + A8 + A11 + A14 + A15) and all the rest in individual groups 
(Figure6). Results showed that all clonal groups that contained more than one isolate 
belonged to the same patient but isolated at different stages of hospitalization, except for 3 
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groups: A17, A18 and A22. A17 included five clonally related ESBL producing E.coli 
isolated from three different patients (p60, p72 and p73), group A18 containing four isolates 
belonging to three different patients; two samples were isolated during July 2012 (p5 and p9) 
and the other two from the same patient (p67). Clonal groups A17 and A18 share 78.2 % 
similarity and most isolates in these two groups were recovered from patients admitted 
consecutively to the hospital. Seven out of the 9 isolates belonging to A17 and A19 carried 
CTX-M-I gene, and exhibited similar resistance profile including resistance to ciprofloxacin, 
cefotaxime, ceftazidime, aztreonam. Group A22 included three strains carrying CTX-M-I 
gene, sharing the same resistance profile (gentamicin, ciprofloxacin, cefotaxime, aztronam 
and ceftazidime), and recovered from patients p19 and p25; both males diagnosed with 
previous malignancy and hospitalized during the same week (between 27
th
 of February and 
2
nd
 of March). These strains can be considered as being epidemiologically related and hence 
patient to patient transmission is probable (Annex1). 
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Figure 5 PFGE analysis of ESBL producing E. coli  collected from patients admitted at UMCRH; lanes 
1-5 and lanes 6-11 represent the molecular patterns generated for different isolates, lanes labeled with L 
represent  the Bio-rad ladder run along the samples for comparison and adjustment of bands sizes. 
 
 
   1        2        3        4        5        L        6        7        8        9       10      11       L      
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Figure 6 Dendrogram of PFGE clusters of ESBL E. coli  isolates. XbaI macrorestriction patterns were analyzed 
using the Dice coefficient and visualized by unweighted-pair group method, using average linkages with 1% 
tolerance and 1% optimization settings. The similarity cutoff of 80% is indicated by a vertical line. PFGE groups 
determined by cluster analysis are numbered from 1-61.Antimicrobial susceptibility, CTX-M group, and patient 
number are included. Three yellow boxes delineate two clonal groups including different patients. 
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4.5 Molecular detection of CTX-M genes  
 
All ESBL isolates were examined by PCR for the presence of blaCTX-M genes, in 
all positive samples as well as the positive control (Figure 7). Forty-eight (80%) out of the 60 
ESBL E. coli strains isolated during the study period were positive for blaCTX-M genes 
from the CTX-M-I group, which indicated high prevalence of CTX-M-1-like beta-lactamase 
production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
500  
       
 
Figure 7 Agarose gel electrophoresis showing representative 
PCR products after CTX-M gene amplification. The first lane 
L shows 100bp DNA marker (Fermentas); lane N shows the 
negative control and lane P shows the positive control;lanes 
1-8 show PCR products of isolates x1 to x8.  
 
 
L      N     P     1      2      3       4      5      6     7      8    
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CHAPTER FIVE 
DISCUSSION 
 
Screening for ESBL producing E.coli was performed on patients admitted to the 
ICU for intestinal and urological surgeries at UMCRH. As part of a blinded study, 60 
ESBL producing samples were isolated through taking three consecutive stool/rectal 
swab cultures prior and post surgery. Their antibiotic resistance profiles were generated, 
and their molecular epidemiology was studied using different approaches including 
PFGE and PCR. All patients that accepted to participate in the study were requested to 
fill a questionnaire that aimed at investigating the possible associated risk factors and 
those patients were followed for two months following surgical interventions to monitor 
the occurrence of any complication.  
Previous studies in different countries including : United Kingdom, Canada and 
USA revealed that the majority of ESBL producers are recovered from critical care 
patients. Additionally, most ESBL associated nosocomial outbreaks originate in the ICU, 
where high antibiotic selection pressure is exerted, and then spread in the hospital by 
clonal dissemination or horizontal transfer of plasmids (Dhillon& Clark, 2012; Canton et 
al, 2003; Pitout et al, 2005). Accordingly, this study aimed at determining the prevalence 
of ESBL production by E.coli among patients admitted to the ICU of UMCRH. The first 
12 isolates from 2012 could not be linked to patients due to lack of patient data from the 
hospital. The remaining 48 isolates belonged to 22 patients (total number was 75) among 
these 22 (30%) were carriers of ESBL producing E.coli. This high prevalence of ESBL 
production revealed an increase in ESBL carriage within ICU patients in Lebanon.  
 33 
 
Previous reports demonstrated that the occurrence of ESBL associated infections 
is increasing in Lebanon. In a retrospective study conducted at a tertiary care center in 
Lebanon, it was shown that the prevalence of ESBL producing E.coli increased 
dramatically from 2.3% in 2000 to reach 18.6% in 2009 (Daoud & Afif, 2011), which 
was in harmony with the results of this study.  
ESBL producing isolates exhibited high rates of antibiotic resistance to different 
classes of antimicrobial agents. This resistance was not limited to third generation 
cephalosporins and aztreonam but also expanded to include significant resistance to 
cefepime (45%) (fourth generation cephalosporin), ciprofloxacin (47%) 
(fluoroquinolone), and gentamicin (37%) (aminoglycoside). Clavulanic acid, an inhibitor 
of β-lactamases, was used in combination with penicillins and cephalosporins to produce 
a highly effective combination, which prolonged the commercial life of these antibiotics 
(Demain & Elainder, 1999; Patterson & Bonomo, 2005). Recently however, the 
effectiveness of these β-lactam/β-lactamase inhibitor combination drugs was challenged 
by resistance mechanisms. This study revealed the decreasing susceptibility to this 
combination since resistance to amoxicillin-clavulanic acid reached 26%. All isolates 
were resistant to cefotaxime, while resistance to ceftazidime was not as significant 
(81.6%), which induced screening for CTX-M enzyme production among all isolates, as 
the CTX-M β-lactamases preferentially hydrolyze cefotaxime over ceftazidime 
(Tzouvelekis et al, 2000). PCR results showed that 80% of the ESBL producing E. coli 
belonged to CTX-M-I group. These results were similar to previous reports revealing the 
predominance and rapid emergence of the CTX-Ms in Lebanon (Moubareck et al, 2005; 
Tabbouche et al, 2011).It is noteworthy that all isolates were susceptible to imipenem 
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(carbapenem), putting carbapenems as the drugs of choice for ESBL associated serious 
infections. This was not however, consistent with the recent finding of emerging 
carbapenem resistance among ESBL isolates in Lebanon (Rahal, 2008; Baroud et al, 
2013). On the other hand, it is quite alarming that 28.2%of the isolates showed 
simultaneous resistance to third-generation cephalosporins, aminoglycosides, and 
fluoroquinolones. Different studies showed that CTX-M positive strains are significantly 
more resistant to different classes of antibiotics than strains lacking the blaCTX-M genes 
(Pitout et al, 2004; Valverde et al, 2006). The blaCTX-M genes are frequently 
encountered in association with genetic structures linked to class 1 integrons, which are 
known to integrate antibiotic resistance gene cassettes responsible for resistance to β-
lactam aminoglycosides, chloramphenicol and sulphonamides (Bonnet, 2004). This could 
explain the multidrug resistance detected among the studied isolates. In 2006, the rising 
incidence of ESBLs in the ICU was reported demonstrating its prevalence in Lebanon 
(Daoud et al, 2006). The results of this study showed that after 7 years the situation did 
not improve, but rather ESBLs’ resistance is growing and the therapeutic alternatives are 
becoming more limited.  
Three rectal swabs pre- and post-surgery were collected for the screening of 
ESBL colonization during the duration of hospital stay for each patient. The results 
obtained showed that the colonization by ESBL producing E.coliwas persistent in 45% of 
the patients, while the other 45% acquired the infection upon surgical intervention, which 
could indicate ESBL contamination within the ICU ward. As for the remaining 10% (p15 
& p43), antibiotic prophylaxis given before and after surgery might have contributed in 
abolishing these MDR isolates specially that the first rectal swab showed ESBL 
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colonization while the second and third were ESBL free. Augmentin was used for 
prophylaxis sin patient p43 and the strain isolated from this patient did not show in vitro 
resistance to AMC (Amoxicillin-clavulanic acid), hence the approach was successful. For 
patient p15 however, rocephine (ceftriaxone) was administered and which also abolished 
the ESBL colonizing strain. As for the remaining patients, given prophylaxis was as per 
standard and included: quinolones, fluoroquinolones, aminoglycosides and different 
cephalosporins depending on the type of surgery performed, the recovered ESBL 
producing strains showed high resistance to all used antibiotics, which led to treatment 
failure and persistant colonization. 
PFGE is the most widely used technique for genotyping ESBL-producing 
Enterobacteriacae (Canton et al, 2002; Lebessi et al, 2002; Patterson &Bonomo, 2005). 
In this study, 56 out of 60 isolates were typed using PFGE. By employing 80% similarity 
cutoff, thirty-one clonal groups were defined (Tenover et al, 1995). Results obtained 
showed that in all strains belonging to the same clonal group were isolated from the same 
patient at different stages of hospitalization, except within three clonal groups A17,A18 
and A22. In a recent study by Doi et al (2012), in a non-outbreak setting clonally-related 
isolates were detected only among a limited number of patients residing in the same unit 
and the majority of strains were not related (Doi et al, 2012). In another study by Qian-
hong in China, among 62 isolates only two showed indistinguishable patterns (Qian-hong 
et al, 2011). These results concurred with our data where clonal diversity is found in a 
non-outbreak situation. It is noteworthy that nine isolates from four different patients 
belonged to the same clonal group at 79.3% similarity cutoff. This is a highly significant 
finding highlighting the occurrence of clonal spread among a limited number of patients, 
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specifically patients p60, p67, p72 andp73, all being hospitalized consecutively during 
the same month in the same unit. Although there is no overlap of temporal hospital stay, 
but patient-to-patient transmission is possible through long-term colonization of health 
care workers or environmental products (Harris et al, 2007). Moreover, the PFGE 
fingerprints generated does not reflect the entire relatedness as ESBL genes mainly 
spread by plasmid transfer. Peirano & Pitout (2010) showed that clonally related strains 
could have diverse resistance profiles and patient-to-patient transmission could be 
underestimated because of plasmid transfer. Harris et al (2007) identified the same or 
similar ESBL encoding plasmids in different clones due to horizontal gene transfer of 
these resistance genes (Harris et al, 2007).In this study, not all strains belonging to the 
same PFGE group carried the plasmid mediated CTX-M-1 group gene, which was in 
accordance with Harris et al (2007) and suggested that further studies are needed to 
elucidate the plasmid profile of these ESBLs. 
Possible risk factors for ESBL colonization were examined to understand the 
possible causes contributing to colonization, and potentially controlling the emergence 
and dissemination of ESBL-producing bacteria. In addition, this monitoring can help 
select which patients should receive ESBL-targeted therapy. Although the number of 
patients included till this stage was not sufficient for the assessment of risk factors but 
results obtained indicated that age above 61 years old, recent hospitalization, diabetes and 
recurrent UTI were frequently encountered among ESBL carriers. Previously published 
studies that consider the history of recent hospitalization, age above 61 years, recurrent 
UTI and diabetes among others as risk factors associated with the colonization or 
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infection with ESBL-producing organisms, especially among CTX-M producers 
(Patterson &Bonomo, 2005). 
Limitations of this study include the small number of patients included. The study 
is still ongoing and additional patients are recruited which can help in achieving a better 
assessment of the prevalence of ESBLs in Lebanon and their associated risk factors. In 
addition, screening was performed on patients admitted for surgeries that did not require 
a lengthy stay in the hospital. Patients with more prolonged exposure in the hospital can 
be at higher risk of acquiring ESBL infections and should be examined as well. 
Furthermore, possible risk factors for ESBL infections included age above 61 years, 
recent previous hospitalization, diabetes and recurrent UTI. A better the assessment of 
risk factors can be achieved through a larger number of patients which will be done in the 
future since this study is still ongoing. Horizontal gene transfer was suspected among 
non-clonally related isolates sharing similar resistance profiles and belonging to CTX-M-
I group. Thus quantification of this transfer through plasmid profiling can help us to 
further understand the genetic relationship among these ESBLs and their mode of rapid 
dissemination. 
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CHAPTER SIX 
CONCLUSION 
 
This study mirrors the molecular characterization of ESBL producing E.coli 
isolated from patients admitted to the ICU for intestinal and urological surgeries. The 
data obtained show increasing prevalence of CTX-M-I group of ESBLs. This group is 
rapidly disseminating worldwide in both hospital and community setting and is 
associated with antibiotic resistance gene cassettes responsible for resistance to a wide 
range of antibiotics. In addition, the results obtained highlight possible patient to patient 
transmission of ESBLs within the ICU of a tertiary care center through longer term 
colonization of health care workers or environmental products. The results obtained call 
for additional infection control measures at this hospital. 
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ANNEX 
key Patient 
number 
Resistance ctx-m 
group 
Age Diabetes UTI cancer Previous 
hospitalization 
1 x1 CIP-CTX-AMC _           
2 x2 GM-FEP-CIP-CTX-ATM-CAZ 1           
3 x3 FEP-CIP-CTX-ATM-CAZ 1           
4 x4 GM-CTX-ATM-CAZ 1           
5 x5 GM-CIP-CTX-ATM-CAZ 1           
6 x6 GM-CTX 1           
7 x7 GM-FEP-CIP-CTX-ATM-CAZ-
AMC 
1           
8 x8 GM-CIP-CTX-ATM-CAZ 1           
9 x9 GM-CIP-CTX-ATM-CAZ 1           
10 x10 CIP-CTX-ATM-CAZ-AMC 1           
11 x11 CTX 1           
12 x12 GM-CTX-AMC 1          
14 p1 CIP-CTX-ATM-CAZ 1   yes yes no yes 
15 p1 CTX-ATM-CAZ 1           
16 p1 CTX-ATM-CAZ 1           
17 p1 CTX-ATM-CAZ 1           
18 p3 FEP-CIP-CTX-ATM-CAZ _ <18 no no no yes 
19 p3 FEP-CIP-CTX-ATM-CAZ _           
20 p3 FEP-CIP-CTX-ATM-CAZ _           
21 p3 FEP-CIP-CTX-ATM-CAZ _           
22 p6 CIP-CTX-ATM _ 41-50 no no no no 
23 p2 CTX-ATM-CAZ-AMC 1 31-40 no no no yes 
24 p12 GM-CIP-CTX-ATM-CAZ-AMC 1 31-40 no no no yes 
25 p12 GM-CIP-CTX-ATM-CAZ 1           
 48 
 
26 p15 CTX-ATM-CAZ-AMC 1 61-70 no no no no 
27 p15 CTX-ATM-CAZ-AMC 1           
28 p17 GM-CTX-ATM-CAZ _ 61-70 no no no no 
29 p19 GM-CIP-CTX-ATM-CAZ 1 61-70 no no yes yes 
30 p19 GM-CIP-CTX-ATM-CAZ 1           
31 p25 GM-FEP-CIP-CTX-ATM-CAZ 1 >70 yes no yes no 
32 p25 GM-FEP-CIP-CTX-ATM-CAZ 1           
33 p27 FEP-CIP-CTX-ATM-CAZ 1 >70 no no yes no 
34 p27 FEP-CIP-CTX-ATM-CAZ 1           
35 p27 FEP-CIP-CTX-ATM-CAZ 1           
36 p33 GM-CIP-CTX 1 51-60 yes no no yes 
37 p33 GM-CIP-CTX 1           
 38 p37 FEP-CIP-CTX-ATM-CAZ-AMC 1 >70 yes no no yes 
 39 p37 FEP-CIP-CTX-ATM-CAZ-AMC 1           
40 p37 FEP-CIP-CTX-ATM-CAZ 1           
41 p38 CTX 1 >70 no no yes yes 
42 p39 GM-CIP-CTX-ATM-CAZ 1 31-40         
43 p39 GM-CIP-CTX-ATM-CAZ-AMC 1           
44 p44 GM-CIP-CTX-ATM-CAZ 1 41-50 yes no no no 
45 p44 FEP-CIP-CTX-ATM-CAZ 1           
 46 p49 FEP-CIP-CTX-ATM-CAZ 1 >70 no no no   
47 p53 GM-FEP-CIP-CTX-ATM-CAZ-
AMC 
1 51-60 no no no yes 
48 p53 GM-FEP-CIP-CTX-ATM-CAZ-
AMC 
1           
 49 p56 FEP-CIP-CTX-ATM 1 61-70 no no no no 
50 p56 FEP-CIP-CTX-ATM 1           
51 p56 GM-FEP-CIP-CTX-ATM-CAZ 1 61-71         
 49 
 
52 p60 FEP-CIP-CTX-ATM-CAZ 1 51-60 no no no yes 
53 p60 FEP-CIP-CTX-ATM-CAZ 1           
54 p60 FEP-CIP-CTX-ATM-CAZ 1           
 55 p67 FEP-CIP-CTX-ATM-CAZ 1 >70 no no no yes 
 56 p67 FEP-CIP-CTX-ATM-CAZ 1           
57 p72 CIP-CTX-ATM-CAZ-AMC _ >70 no no no no 
58 p72 CIP-CTX-ATM-CAZ-AMC _           
61 p72 FEP-CIP-CTX-ATM-CAZ _           
 59 p73 GM-CIP-CTX-ATM-CAZ _ 61-70 no no no no 
60 p73 GM-CIP-CTX-ATM-CAZ-AMC _           
 
 
 
 
